Thought Leadership

Charlotte Barker (Editor, BioInsights) speaks to Elie Hanania, PhD (Vice President of Process Development Viral Vector Technologies, Avid Bioservices) about the current status and future manufacturing of AAV-based gene therapies, including how to streamline large-scale manufacturing.

Adapting an existing facility for viral vector manufacturing purposes presents challenges that have the potential to impact safety and integrity. A dedicated facility, built from the ground up, enables CDMOs to address areas of concern specific to viral vectors. Learn more about how Avid’s purpose-built approach is answering the industry need for quality viral vector manufacturing.

Learn more about the drivers motivating Avid Bio’s entrance into the viral vector space, and the unique and differentiating value the company can offer cell and gene therapy developers.